# Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

> **NCT00683306** · — · APPROVED_FOR_MARKETING · sponsor: **AstraZeneca**

## Conditions studied

- Non Small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** ZD1839 (Iressa)

## Key facts

- **NCT ID:** NCT00683306
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2018-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683306, "Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00683306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*